This ADC was used in combination with anti-PD-1 mAb nivolumab or pembrolizumab and varlilumab (307, 308), an agonistic anti-CD27 mAb, for the treatment of advanced melanoma (NCT02302339). This evidence concerns the gene PDCD1 and melanoma.